"Pfizer posted adjusted EPS of $0.66 against a $0.57 consensus on $17.56 billion in revenue, with the top line dipping just 1.2% year over year. The non-COVID book did the heavy lifting, growing 9% operationally."
"Moderna told a leaner story. Revenue landed at $678 million, down 29.08% year over year, while the loss per share of $2.11 still beat the $2.62 estimate."
"Albert Bourla closed the $7 billion Metsera deal for ultra-long-acting GLP-1 obesity assets and is planning 10 pivotal trial starts in 2026 from that platform alone."
"The intismeran autogene melanoma program with Merck showed a 49% reduction in risk of recurrence or death versus Keytruda alone in the five-year Phase 2b readout."
Pfizer reported a slight revenue dip but strong growth in its non-COVID portfolio, driven by obesity drugs and other therapies. Adjusted EPS was $0.66, exceeding expectations. Moderna faced a significant revenue decline, down 29.08%, with a loss per share of $2.11. The company focused on cost reductions and international expansion, establishing new manufacturing sites. Pfizer's strategic pivot includes a $7 billion deal for obesity assets, while Moderna continues to develop mRNA therapies, including a promising melanoma program despite regulatory challenges.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]